Abstract According to the 2008 World Health Organization classification system for
hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic …

The primary disease process in myelofibrosis with myeloid metaplasia (MMM) is clonal
myeloproliferation with varying degrees of phenotypic differentiation. This is …

Single-agent thalidomide (THAL) at “conventional” doses (> 100 mg/d) has been evaluated
in myelofibrosis with myeloid metaplasia (MMM) based on its antiangiogenic properties and …

Background: Thalidomide is best known as a major teratogen that caused birth defects in up
to 12,000 children in the 1960s. More recently, this agent has been approved by the US …

Thalidomide, a glutamic acid derivative, was withdrawn from clinical use in 1962 due to its
severe teratogenic effects. Its recent reinstitution in clinical practice was related to its benefits …

Thalidomide (α-N-[phthalimido] glutarimide) was first synthesized in 1953 by Ciba, a Swiss
pharmaceutical firm, and then in 1954 by Kunz, a chemist at Chemie Grünenthal, a German …

Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its
activity in cancer. After its success in myeloma, it has been investigated in other plasma cell …

Myelofibrosis with myeloid metaplasia (MMM) is uniquely characterized by macroscopic
bone marrow stromal changes that are believed to be both reactive and cytokine mediated …

Trials to determine the effect of thalidomide in patients with Myelofibrosis with Myeloid
Metaplasia (MMM) have produced inconclusive results due to different criteria for response …

The recent discovery of JAK2 and/or MPL mutations in polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF) has had a major impact on how we …